Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>Events>This Event
  Events - June 2013

5th Annual Drug Development Congress 2013

10 Jun 2013 - 11 Jun 2013 - Geneva, Switzerland

Bookmark and Share

Oxford Global Conferences are proud to present the 5th Annual Drug Development Congress, taking place on the 10th & 11th June in Geneva.

It is estimated that the average drug costs the world’s leading pharmaceutical companies at least $4 billion to develop. Amid fears that the current large pharma model is not working, this event focuses on attempts to break down discovery and development boundaries and promote knowledge share between therapy areas.

On Day One, our expert speakers will discuss key areas for improvement in drug development, including translational modelling, safety & efficacy testing and reducing timelines for biopharmaceutical pipelines. Topics will include assay development, pharmacokinetic challenges and updates on the latest NGS applications.

Day Two will cover the latest methods to improve decision making in drug development; from advances in biomarker technology, to the integration of safety studies earlier in the pipeline. Our expert speakers will also present collaboration case studies, discussing both external and internal attempts to harness complimentary skills and reduce late stage failure.

To maintain the extensive networking opportunities enjoyed by last year’s delegates, the development congress will once again be co-located with our discovery summit. The 14th Annual Drug Discovery Leaders’ Summit has a long-held association with the leaders in medicinal chemistry and drug design. This year’s event will focus on innovation. Experts will discuss how new developments in screening, assay development, structure-activity analysis and anti-target effect prediction will influence the success of discovery portfolios.

Further information
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Promising Drug Combination for Advanced Prostate Cancer
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.
A Cellular Symphony Responsible for Autoimmune Disease
Broad Institute researchers have used a novel approach to increase our understanding of the immune system as a whole.
When it Comes to Breast Cancer, Common Pigeon is No Bird Brain
If pigeons went to medical school and specialized in pathology or radiology, they’d be pretty good at distinguishing digitized microscope slides and mammograms of normal vs. cancerous breast tissue, a new study has found.
Editing of LIMS Data Made Faster and More Efficient in Matrix Gemini
The latest version of the Matrix Gemini LIMS (Laboratory Information Management System) from Autoscribe Informatics now provides faster and more efficient editing of LIMS data by eliminating the need for a second editing screen.
University of Edinburgh, Selcia Achieve Key Milestones in Drug Development Program
Scientists from the University of Edinburgh, working with Selcia, have successfully passed the 20-month milestone targets of a 30-month Wellcome Trust SDDi £2.5 million project to design novel treatments for sleeping sickness.
Red Clover Genome to Help Restore Sustainable Farming
The Genome Analysis Centre (TGAC) in collaboration with IBERS, has sequenced and assembled the DNA of red clover to help breeders improve the beneficial traits of this important forage crop.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos